drugset / Trial / NCT03201757

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

NCT03201757

Phase 3 Completed 523 enrolled Alkermes, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder

Timeline

Start
2017-06-15
Primary completion
2023-09-06
Completion
2023-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule Oral
Subject Samidorphan Small molecule Oral